Characteristics | N (%) or median (range) |
---|---|
No. of patients | 132 |
Age (years) | 65.5 (41.7–84.1) |
Sex | Â |
Male | 75 (56.8) |
Female | 57 (43.2) |
ECOG | Â |
0 | 50 (37.9) |
1–2 | 82 (62.1) |
Histology | Â |
Adenocarcinoma | 131 (99.2) |
Undifferentiated carcinoma | 1 (0.8) |
Location of primary tumor | Â |
Head | 59 (44.7) |
Other | 73 (55.3) |
Disease extent | Â |
Borderline resectable | 41 (31.1) |
Locally advanced | 91 (69.9) |
Baseline CA 19-9 (U/mL) | 183.9 (1.0–7358.4) |
Induction chemotherapy duration (months) | 4 (1–18) |
Induction chemotherapy regimen | Â |
mFFX | 103 (78.0) |
GnP | 21 (15.8) |
mFFX and GnP | 5 (3.8) |
mFFX plus other | 1 (0.8) |
GnP plus other | 1 (0.8) |
Other | 1 (0.8) |
SBRT dose and fractionation | Â |
33Â Gy in 5 fractions | 128 (97.0) |
30Â Gy 5 fractions | 2 (1.4) |
36Â Gy in 5 fractions | 1 (0.8) |
30.5Â Gy in 5 fractions | 1 (0.8) |
PTV (cm3) | 132.0 (13.1–428.3) |
Surgically Resected | 90 (68.2) |
Whipple procedure | 54 (60.0) |
Distal prancreatectomy | 31 (34.4) |
Total pancreatectomy | 5 (5.6) |